Rimexolone

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O7M2E4264D, chemically known as 11beta-hydroxy-16alpha,17alpha-dimethyl-17-propionylandrosta-1,4-dien-3-one but generally known as rimexolone, which bears US NIH Compound Identifier 39507. European Medicines Agency schedules Rimexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10323MIG. The term RIMEXOLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules rimexolone in its Anatomical Therapeutic Chemical (ATC) Classification. RIMEXOLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rimexolone under HS 29372900 and SITC 54153. As of Q4 2014, RIMEXOLONE remains the US FDA Preferred Term for this commodity. Rimexolone bears US NLM identifiers UMLS ID C0140594 and NCI Concept Code C47705. SMILES: OC1C2C(C3C(C(C(C3)C)(C)C(=O)CC)(C1)C)CCC1=CC(=O)C=CC21C.